Welgene Biotech Co (ROCO:6661) Stock Based Compensation: NT$0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6661 Welgene Biotech Co Ltd ROCO:6661
74 GF Score
Price NT$17.60
GF Value NT$30.25
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Welgene Biotech Co Stock Based Compensation?

Welgene Biotech Co ROCO:6661 74 Stock Based Compensation is NT$0.0 Mil as of Mar. 2026. GuruFocus rates ROCO:6661 with a GF Score™ of 74/100 and a GF Value™ of NT$30.25 (Possible Value Trap). The stock has 4 warning signs investors should review.

Welgene Biotech Co's Stock Based Compensation for the three months ended in Mar. 2026 was NT$0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was NT$0.0 Mil.

Welgene Biotech Co Stock Based Compensation Related Terms

Welgene Biotech Co Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Welgene Biotech Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Welgene Biotech Co Stock Based Compensation Chart

Welgene Biotech Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Welgene Biotech Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ROCO:6661
74GF Score
Welgene Biotech Co Ltd ROCO:6661
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Welgene Biotech Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$0.0 Mil.

What does a Stock Based Compensation of NT$0.0 Mil mean?
Welgene Biotech Co (ROCO:6661) has a Stock Based Compensation of NT$0.0 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Welgene Biotech Co and its competitors.
Is Welgene Biotech Co's Stock Based Compensation too high?
Welgene Biotech Co's current Stock Based Compensation is NT$0.0 Mil. Overall, Welgene Biotech Co has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Welgene Biotech Co's Stock Based Compensation compare to TMO and DHR?
Welgene Biotech Co's Stock Based Compensation of NT$0.0 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Medical Diagnostics & Research company?
A good Stock Based Compensation depends on the Medical Diagnostics & Research industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Welgene Biotech Co and its competitors. Welgene Biotech Co's current Stock Based Compensation is NT$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Welgene Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Welgene Biotech Co (ROCO:6661) is currently considered Possible Value Trap. The stock's GF Value™ is NT$30.25, compared to a current price of NT$17.60 — trading 41.8% below its estimated fair value. The current Stock Based Compensation is NT$0.0 Mil. Welgene Biotech Co's overall GF Score™ is 74/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Welgene Biotech Co (ROCO:6661), the current Stock Based Compensation is NT$0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Welgene Biotech Co (ROCO:6661) Overvalued in 2026?

Based on GuruFocus' analysis, Welgene Biotech Co stock appears to be undervalued. The current stock price of NT$17.60 is trading 41.8% below its estimated GF Value™ of NT$30.25. GuruFocus considers Welgene Biotech Co to be Possible Value Trap.

Key valuation signals for ROCO:6661:

  • Stock Based Compensation: NT$0.0 Mil
  • GF Value™: NT$30.25 vs. price of NT$17.60 (41.8% below fair value)
  • GF Score™: 74/100 with 4 warning signs

No single metric tells the full story. See the ROCO:6661 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Welgene Biotech Co Business Description

Address No. 3, Yuanqu Street, 12th Floor, Nangang District, Taipei, TWN, 115603
Welgene Biotech Co Ltd is engaged in providing genetic and biotechnology testing services and related products. Its offerings include next-generation sequencing (NGS) services, DNA microarray and PCR-based testing solutions, biotechnology reagents, diagnostic products, and laboratory instruments. The company also engages in the trading of medical and biotechnology equipment.
74GF Score

Get the complete analysis for ROCO:6661

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$17.60
Price
NT$30.25
GF Value